Atomoxetine to reduce freezing of gait in Parkinson's disease by targeting the brain's noradrenaline system

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, randomized comparison gives people with Parkinson's disease and daily freezing of gait either atomoxetine or a matching placebo and tracks changes in walking and symptoms over time. Participants visit the study site for clinical measurements, standardized walking assessments, MRI scanning, and questionnaires about anxiety, stress, and quality of life. Participants must be on stable dopaminergic treatment and able to walk 10 meters unaided in the ON state, and study procedures include multi-modal motor and imaging measures to probe noradrenergic involvement. The trial aims to link clinical changes in freezing with brain noradrenaline markers to determine whether modulating that system improves gait.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 years or older;
* Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;
* Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;
* Presence of FOG symptoms on a daily basis;
* Ability to walk for 10-meters unaided in the dopaminergic ON-state;
* Ability to provide written informed consent in accordance with ICH-GCP and local regulations;
* Willing and able to undergo all clinical trial assessments.

Exclusion Criteria:

* Current and/or previous (within 3 months) participation in a clinical trial;
* Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);
* Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);
* Severe cognitive impairment hampering the ability to comply with the study protocol;
* Active psychosis that would impact the ability to comply with the study protocol;
* Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc \> 500ms Bazett-formula) and channelopathies that in the opinion of the study PI would significantly compromise participant safety;
* Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke;
* Hepatic or renal insufficiency that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
* Narrow angle glaucoma;
* (History of) pheochromocytoma;
* Use of noradrenergic agents;
* Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine);
* Use of high dose salbutamol (or other beta2 agonists) that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
* Pregnancy and/or breastfeeding;
* Known hypersensitivity to atomoxetine.

Where it's running

• Radboudumc
  Nijmegen, Gelderland, Netherlands Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Automated language analysis to help diagnose neurodegenerative diseases

  A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Bari · NCT07906769

• Brain alpha-synuclein PET imaging in Parkinson's patients and healthy seniors

  This open-label study tests a radioactive tracer called [18F]MK-0947 to see how it behaves in the brains of people with Parkinson's disease compared with healthy elderly volunteers.

  Recruiting Phase 1 XingImaging, LLC · New Haven, Connecticut · NCT07880379

• Parkinson’s self-sufficiency and rehabilitation in a Czech spa setting

  This intervention tests whether a Czech self-sufficiency test can be used with people with Parkinson’s disease and sees how spa-based rehabilitation affects independence, cognition, balance, and walking.

  Recruiting Palacky University · Olomouc · NCT07872202

• Imaging PD progression with [18F]AV-133 using high- and standard-resolution PET

  This study tests how [18F]AV-133 PET imaging changes over 12 months in people with Parkinson's disease and a small group of healthy controls.

  Recruiting Phase 2 Michael J. Fox Foundation for Parkinson's Research · New Haven, Connecticut · NCT07830654

• Microelectrode-based brain stimulation for Parkinson’s and essential tremor

  This early feasibility test checks a new microelectrode-based brain stimulation method in adults with Parkinson’s disease or essential tremor who are already getting deep brain stimulation implants.

  Recruiting Lund University · Lund, Skåne County · NCT07820189

• Sleep and adaptive DBS in Parkinson’s disease

  This study tests whether adjusting adaptive deep brain stimulation during sleep can improve sleep quality and brain activity in people with Parkinson’s disease who already have DBS.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07808346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.